- Home
- CTR vs OMER Comparison
CTR vs OMER Comparison
Compare CTR & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTR
- OMER
- Stock Information
- Founded
- CTR 2012
- OMER 1994
- Country
- CTR United States
- OMER United States
- Employees
- CTR N/A
- OMER N/A
- Industry
- CTR Investment Managers
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- CTR Finance
- OMER Health Care
- Exchange
- CTR Nasdaq
- OMER Nasdaq
- Market Cap
- CTR 271.3M
- OMER 226.0M
- IPO Year
- CTR N/A
- OMER 2009
- Fundamental
- Price
- CTR $40.26
- OMER $3.64
- Analyst Decision
- CTR
- OMER Hold
- Analyst Count
- CTR 0
- OMER 2
- Target Price
- CTR N/A
- OMER N/A
- AVG Volume (30 Days)
- CTR 17.6K
- OMER 260.3K
- Earning Date
- CTR 01-01-0001
- OMER 08-07-2024
- Dividend Yield
- CTR 6.82%
- OMER N/A
- EPS Growth
- CTR N/A
- OMER N/A
- EPS
- CTR N/A
- OMER N/A
- Revenue
- CTR N/A
- OMER N/A
- Revenue This Year
- CTR N/A
- OMER N/A
- Revenue Next Year
- CTR N/A
- OMER N/A
- P/E Ratio
- CTR N/A
- OMER N/A
- Revenue Growth
- CTR N/A
- OMER N/A
- 52 Week Low
- CTR $27.00
- OMER $0.92
- 52 Week High
- CTR $41.15
- OMER $5.68
- Technical
- Relative Strength Index (RSI)
- CTR 51.18
- OMER 36.03
- Support Level
- CTR $40.18
- OMER $4.00
- Resistance Level
- CTR $41.05
- OMER $4.23
- Average True Range (ATR)
- CTR 0.52
- OMER 0.24
- MACD
- CTR 0.05
- OMER -0.03
- Stochastic Oscillator
- CTR 36.25
- OMER 1.33
About CTR ClearBridge MLP and Midstream Total Return Fund Inc.
ClearBridge Energy MLP Total Return Fund is the United States-based non-diversified, closed-end management investment company. Its investment objective is to provide a high level of total return consisting of cash distributions and capital appreciation.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.